September 3, 2013
•Oncothyreon (ONTY +2.1%) initiates a Phase 1 trial of a ONT-380/ Herceptin combo in patients with brain metastases from HER2+ breast cancer. ONT-380 is developed in collaboration with Array BioPharma (ARRY +3.6%).
•The objective of the trial will be to determine "the maximum-tolerated dose and recommended Phase 2 dose and schedule." (PR)
The slide for this blew my mind. 100% complete responses for the arm that received Herceptin in combination with ONT-380, and they stayed tumor-free for over 50 days. AND this was after the patients had already received the standard of care. Anyone know how many patients got the combo and whether the complete responses include responses to brain metastases? Thanks in advance.
Because I realize my previous post wasn't specific and because it may have been incorrect, I'll try again: slide six from the overview to announce the partnership between Oncothyreon and Array involving the previously-named ARRY-380 very much impresses me because the preclinical arm that received both Herceptin and ONT-380 had 100% complete responses from the patients and they stayed tumor-free for more than fifty days. It would be nice to know if they had been pretreated and how many patients were in this arm. It would also be nice to know if this complete response measurement included brain metastases. Again, thanks in advance.